Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet (Alogliptin FDC With Metformin) in Russian Healthy Subjects

Next Previous
Search
Trial Profile

An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet (Alogliptin FDC With Metformin) in Russian Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alogliptin (Primary) ; Alogliptin/metformin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Takeda

    • Most Recent Events

    • 01 Jun 2016 Status changed from not yet recruiting to completed.
    • 10 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 10 Feb 2016 Planned primary completion date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top